Implementation of biomarker testing is key to the success of precision medicine. The success of therapies based on immuno-oncology, with over six indications in recent years (predominantly lung cancer), has highlighted the need for PD-L1 biomarker testing and the challenges it raises for implementation. In this webinar, we will discuss the adoption of PD-L1 testing in Europe using Germany and Italy as examples, to understand how different environments can generate different adoption rates, and look at how the process could be optimized. Listen to the webinar to learn:
- An overview of the pathology testing landscape in Germany and Italy
- The current PD-L1 testing landscape in Germany and Italy
- Market differences, gap analysis and possible scenarios
